Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1305

    1.

    Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.

    Cadarette SM, Katz JN, Brookhart MA, Stürmer T, Stedman MR, Solomon DH.

    Ann Intern Med. 2008 May 6;148(9):637-46.PMID: 18458276 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.

    Watts NB, Worley K, Solis A, Doyle J, Sheer R.

    J Manag Care Pharm. 2004 Mar-Apr;10(2):142-51.PMID: 15032563 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

    Stevenson M, Jones ML, De Nigris E, Brewer N, Davis S, Oakley J.

    Health Technol Assess. 2005 Jun;9(22):1-160. Review.PMID: 15929857 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Health-economic comparison of three recommended drugs for the treatment of osteoporosis.

    Brecht JG, Kruse HP, Möhrke W, Oestreich A, Huppertz E.

    Int J Clin Pharmacol Res. 2004;24(1):1-10.PMID: 15575171 [PubMed - indexed for MEDLINE]Related articles

    5.

    Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.

    Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R.

    Osteoporos Int. 2007 Jan;18(1):25-34. Epub 2006 Nov 15.PMID: 17106785 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Summaries for patients. Drug therapy for osteoporosis.

    [No authors listed]

    Ann Intern Med. 2008 May 6;148(9):I28. No abstract available. PMID: 18458273 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Aging bone and osteoporosis: strategies for preventing fractures in the elderly.

    Ettinger MP.

    Arch Intern Med. 2003 Oct 13;163(18):2237-46. Review.PMID: 14557222 [PubMed - indexed for MEDLINE]Related articles

    8.

    Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

    Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators.

    J Bone Miner Res. 2005 Sep;20(9):1514-24. Epub 2005 May 16.PMID: 16059623 [PubMed - indexed for MEDLINE]Related articles

    9.

    Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.

    Iwamoto J, Takeda T, Sato Y.

    Curr Med Res Opin. 2006 May;22(5):919-28. Review.PMID: 16709313 [PubMed - indexed for MEDLINE]Related articles

    10.

    Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.

    Watts NB, Geusens P, Barton IP, Felsenberg D.

    J Bone Miner Res. 2005 Dec;20(12):2097-104. Epub 2005 Aug 8.PMID: 16294263 [PubMed - indexed for MEDLINE]Related articles

    11.

    Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.

    Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R; ICARO Study Group.

    J Bone Miner Res. 2006 Oct;21(10):1565-70.PMID: 16995811 [PubMed - indexed for MEDLINE]Related articles

    12.

    Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.

    Blouin J, Dragomir A, Moride Y, Ste-Marie LG, Fernandes JC, Perreault S.

    Br J Clin Pharmacol. 2008 Jul;66(1):117-27. Epub 2008 May 6.PMID: 18460036 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.

    Brookhart MA, Avorn J, Katz JN, Finkelstein JS, Arnold M, Polinski JM, Patrick AR, Mogun H, Solmon DH.

    Am J Med. 2007 Mar;120(3):251-6.PMID: 17349448 [PubMed - indexed for MEDLINE]Related articles

    14.

    Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.

    Tosteson AN, Burge RT, Marshall DA, Lindsay R.

    Am J Manag Care. 2008 Sep;14(9):605-15.PMID: 18778176 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

    Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL.

    Bone. 2007 Apr;40(4):843-51. Epub 2006 Dec 19.PMID: 17182297 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

    JAMA. 2006 Dec 27;296(24):2927-38.PMID: 17190893 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.

    Goeree R, Blackhouse G, Adachi J.

    Curr Med Res Opin. 2006 Jul;22(7):1425-36.PMID: 16834841 [PubMed - indexed for MEDLINE]Related articles

    18.

    Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.

    Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, Agnusdei D, Gentilella R, Nuti R; ICARO Study Group.

    Osteoporos Int. 2008 Aug;19(8):1219-23. Epub 2008 Feb 20.PMID: 18286217 [PubMed - indexed for MEDLINE]Related articles

    19.

    Medical treatment of vertebral osteoporosis.

    Lippuner K.

    Eur Spine J. 2003 Oct;12 Suppl 2:S132-41. Epub 2003 Sep 17. Review.PMID: 13680313 [PubMed - indexed for MEDLINE]Related articles

    20.

    Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.

    Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL.

    Bone. 2009 May;44(5):758-65. Epub 2009 Jan 9.PMID: 19168160 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data